---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031425"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:13:58.310958+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q3 net loss $10.6M; advances cardiac ablation devices toward 510(k) and first-in-human

## Summary
- GAAP net loss of $10.6M for Q3 2023 vs $18.0M in Q3 2022; non-GAAP net loss $8.5M vs $16.8M.
- Cash and cash equivalents $50.4M as of Sept 30, 2023 vs $69.2M a year ago; Q3 cash burn $8.7M.
- Plan to file 510(k) for cardiac ablation surgical clamp and initiate first-in-human catheter procedure between Dec 2023 and Q1 2024.
- Appointed Dr. Niv Ad as Chief Science Officer, Cardiac Surgery to lead clinical strategy.
- Completed treatment of 21 subjects in thyroid clinical feasibility study; started additional group Nov 7, 2023.

## SEC filing metadata
- accession: 0001437749-23-031425
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/0001437749-23-031425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/plse20231108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031425
- JSON: https://secwatch.observer/filing/0001437749-23-031425.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031425.txt

## Key facts
- Earnings Releases
  PULSE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income ($10.6) million.
  - Period: the third quarter ended September 30, 2023
  - Net income: ($10.6) million
  - Result: reported results
  source text: GAAP net loss for the three months ended September 30, 2023 was ($10.6) million compared to ($18.0) million for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774923031425/0001437749-23-031425-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.